Seagate Technology Holdings PLC vs BIO-TECHNE Corp — how do they compare? Seagate Technology Holdings PLC trades at $787.3 (market cap $183.64B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Seagate Technology Holdings PLC is far larger — about 16.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold Seagate Technology Holdings PLC for 41 Days and BIO-TECHNE Corp for 63 Days on average.
| STX | TECH | |
|---|---|---|
Market Cap | $183.64B | $11.37B |
Volume | 4,409,190 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $1.09K | $72.61 |
52-Week Low | $211.63 | $43.31 |
Typical Hold Time | 41 Days | 63 Days |
Enterprise Value | $185.79B | $11.40B |
Dividend Yield | 0.37% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
STX trades at $774.83, down 3.82% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $5.71 vs. $5.10, and robust profitability metrics including 26.11% net margin and 371.53% ROE. Technical indicators signal bearish momentum with price near support at $773, while analyst consensus remains positive with 53.85% buy ratings and $1,130 price target.
Despite near-term competitive pressures, STX maintains strong earnings momentum and leadership in AI storage markets. The primary risk involves Toshiba's capacity expansion potentially eroding pricing power, but projected 2026 revenue growth to $12.2B and net income of $3.2B support long-term upside. Current valuation at 58.1 P/E reflects growth expectations amid technical weakness.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →